Powers Harry Ross, Bachar Moshe, Savage Natasha, Toscano Michael, Dainer Paul M
Department of Medicine, Medical College of Georgia, Georgia Regents University , Augusta, GA, USA.
Department of Pathology, Medical College of Georgia, Georgia Regents University , Augusta, GA, USA ; Charlie Norwood Veteran Affairs Medical Center , Augusta, GA, USA.
Hematol Rep. 2014 Sep 30;6(3):5516. doi: 10.4081/hr.2014.5516. eCollection 2014 Aug 26.
Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.
急性髓系白血病（AML）是一种髓系祖细胞的血液系统恶性肿瘤，会破坏正常的造血功能。目前的化疗方案在许多情况下可导致完全缓解；然而，对于难治性急性髓系白血病，尚无标准的有效治疗方法。低甲基化药物阿扎胞苷在少数此类病例中有效。我们报告一名57岁的菲律宾男性急性髓系白血病患者，他对两种诱导化疗方案均耐药；然而，在接受阿扎胞苷姑息治疗后实现了完全缓解。我们报告此病例以证明阿扎胞苷在难治性急性髓系白血病中的疗效。尽管已显示阿扎胞苷在改善总生存期方面的有效性，但该病例证明了其对高危AML缓解诱导的作用。需要进一步研究来确定阿扎胞苷可作为有效治疗的急性髓系白血病亚组，并识别其他可能增强其作用的靶向药物。
